Cargando…

The Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence Estimates: Findings From a US National Cohort, February 2022

BACKGROUND: Passive, case-based surveillance underestimates the true extent of active infections in the population due to undiagnosed and untested cases, the exclusion of probable cases diagnosed point-of-care rapid antigen tests, and the exclusive use of at-home rapid tests which are not reported a...

Descripción completa

Detalles Bibliográficos
Autores principales: Qasmieh, Saba A, Robertson, McKaylee M, Rane, Madhura S, Shen, Yanhan, Zimba, Rebecca, Picchio, Camila A, Parcesepe, Angela M, Chang, Mindy, Kulkarni, Sarah G, Grov, Christian, Nash, Denis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822564/
https://www.ncbi.nlm.nih.gov/pubmed/36240020
http://dx.doi.org/10.2196/38196
_version_ 1784865974941384704
author Qasmieh, Saba A
Robertson, McKaylee M
Rane, Madhura S
Shen, Yanhan
Zimba, Rebecca
Picchio, Camila A
Parcesepe, Angela M
Chang, Mindy
Kulkarni, Sarah G
Grov, Christian
Nash, Denis
author_facet Qasmieh, Saba A
Robertson, McKaylee M
Rane, Madhura S
Shen, Yanhan
Zimba, Rebecca
Picchio, Camila A
Parcesepe, Angela M
Chang, Mindy
Kulkarni, Sarah G
Grov, Christian
Nash, Denis
author_sort Qasmieh, Saba A
collection PubMed
description BACKGROUND: Passive, case-based surveillance underestimates the true extent of active infections in the population due to undiagnosed and untested cases, the exclusion of probable cases diagnosed point-of-care rapid antigen tests, and the exclusive use of at-home rapid tests which are not reported as part of case-based surveillance. The extent in which COVID-19 surveillance may be underestimating the burden of infection is likely due to time-varying factors such as decreased test-seeking behaviors and increased access to and availability of at-home testing. OBJECTIVE: The objective of this study is to estimate the prevalence of SARS-CoV-2 based on different definitions of a case to ascertain the extent to which cases of SARS-CoV-2 may be underestimated by case-based surveillance. METHODS: A survey on COVID-19 exposure, infection, and testing was administered to calculate point prevalence of SARS-CoV-2 among a diverse sample of cohort adults from February 8, 2022, to February 22, 2022. Three-point prevalence estimates were calculated among the cohort, as follows: (1) proportion positives based on polymerase chain reaction (PCR) and rapid antigen tests; (2) proportion positives based on testing exclusively with rapid at-home tests; and (3) proportion of probable undiagnosed cases. Test positivity and prevalence differences across booster status were also examined. RESULTS: Among a cohort of 4328, there were a total of 644 (14.9%) cases. The point prevalence estimate based on PCR or rapid antigen tests was 5.5% (95% CI 4.8%-6.2%), 3.7% (95% CI 3.1%-4.2%) based on at-home rapid tests, and 5.7% (95% CI 5.0%-6.4%) based on the case definition of a probable case. The total point prevalence across all definitions was 14.9% (95% CI 13.8%-16.0%). The percent positivity among PCR or rapid tests was 50.2%. No statistically significant differences were observed in prevalence between participants with a COVID-19 booster compared to fully vaccinated and nonboosted participants except among exclusive at-home rapid testers. CONCLUSIONS: Our findings suggest a substantial number of cases were missed by case-based surveillance systems during the Omicron B.1.1.529 surge, when at-home testing was common. Point prevalence surveys may be a rapid tool to be used to understand SARS-CoV-2 prevalence and would be especially important during case surges to measure the scope and spread of active infections in the population.
format Online
Article
Text
id pubmed-9822564
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-98225642023-01-07 The Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence Estimates: Findings From a US National Cohort, February 2022 Qasmieh, Saba A Robertson, McKaylee M Rane, Madhura S Shen, Yanhan Zimba, Rebecca Picchio, Camila A Parcesepe, Angela M Chang, Mindy Kulkarni, Sarah G Grov, Christian Nash, Denis JMIR Public Health Surveill Short Paper BACKGROUND: Passive, case-based surveillance underestimates the true extent of active infections in the population due to undiagnosed and untested cases, the exclusion of probable cases diagnosed point-of-care rapid antigen tests, and the exclusive use of at-home rapid tests which are not reported as part of case-based surveillance. The extent in which COVID-19 surveillance may be underestimating the burden of infection is likely due to time-varying factors such as decreased test-seeking behaviors and increased access to and availability of at-home testing. OBJECTIVE: The objective of this study is to estimate the prevalence of SARS-CoV-2 based on different definitions of a case to ascertain the extent to which cases of SARS-CoV-2 may be underestimated by case-based surveillance. METHODS: A survey on COVID-19 exposure, infection, and testing was administered to calculate point prevalence of SARS-CoV-2 among a diverse sample of cohort adults from February 8, 2022, to February 22, 2022. Three-point prevalence estimates were calculated among the cohort, as follows: (1) proportion positives based on polymerase chain reaction (PCR) and rapid antigen tests; (2) proportion positives based on testing exclusively with rapid at-home tests; and (3) proportion of probable undiagnosed cases. Test positivity and prevalence differences across booster status were also examined. RESULTS: Among a cohort of 4328, there were a total of 644 (14.9%) cases. The point prevalence estimate based on PCR or rapid antigen tests was 5.5% (95% CI 4.8%-6.2%), 3.7% (95% CI 3.1%-4.2%) based on at-home rapid tests, and 5.7% (95% CI 5.0%-6.4%) based on the case definition of a probable case. The total point prevalence across all definitions was 14.9% (95% CI 13.8%-16.0%). The percent positivity among PCR or rapid tests was 50.2%. No statistically significant differences were observed in prevalence between participants with a COVID-19 booster compared to fully vaccinated and nonboosted participants except among exclusive at-home rapid testers. CONCLUSIONS: Our findings suggest a substantial number of cases were missed by case-based surveillance systems during the Omicron B.1.1.529 surge, when at-home testing was common. Point prevalence surveys may be a rapid tool to be used to understand SARS-CoV-2 prevalence and would be especially important during case surges to measure the scope and spread of active infections in the population. JMIR Publications 2022-12-27 /pmc/articles/PMC9822564/ /pubmed/36240020 http://dx.doi.org/10.2196/38196 Text en ©Saba A Qasmieh, McKaylee M Robertson, Madhura S Rane, Yanhan Shen, Rebecca Zimba, Camila A Picchio, Angela M Parcesepe, Mindy Chang, Sarah G Kulkarni, Christian Grov, Denis Nash. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 27.12.2022. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Public Health and Surveillance, is properly cited. The complete bibliographic information, a link to the original publication on https://publichealth.jmir.org, as well as this copyright and license information must be included.
spellingShingle Short Paper
Qasmieh, Saba A
Robertson, McKaylee M
Rane, Madhura S
Shen, Yanhan
Zimba, Rebecca
Picchio, Camila A
Parcesepe, Angela M
Chang, Mindy
Kulkarni, Sarah G
Grov, Christian
Nash, Denis
The Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence Estimates: Findings From a US National Cohort, February 2022
title The Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence Estimates: Findings From a US National Cohort, February 2022
title_full The Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence Estimates: Findings From a US National Cohort, February 2022
title_fullStr The Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence Estimates: Findings From a US National Cohort, February 2022
title_full_unstemmed The Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence Estimates: Findings From a US National Cohort, February 2022
title_short The Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence Estimates: Findings From a US National Cohort, February 2022
title_sort importance of incorporating at-home testing into sars-cov-2 point prevalence estimates: findings from a us national cohort, february 2022
topic Short Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822564/
https://www.ncbi.nlm.nih.gov/pubmed/36240020
http://dx.doi.org/10.2196/38196
work_keys_str_mv AT qasmiehsabaa theimportanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT robertsonmckayleem theimportanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT ranemadhuras theimportanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT shenyanhan theimportanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT zimbarebecca theimportanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT picchiocamilaa theimportanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT parcesepeangelam theimportanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT changmindy theimportanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT kulkarnisarahg theimportanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT grovchristian theimportanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT nashdenis theimportanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT qasmiehsabaa importanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT robertsonmckayleem importanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT ranemadhuras importanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT shenyanhan importanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT zimbarebecca importanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT picchiocamilaa importanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT parcesepeangelam importanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT changmindy importanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT kulkarnisarahg importanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT grovchristian importanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022
AT nashdenis importanceofincorporatingathometestingintosarscov2pointprevalenceestimatesfindingsfromausnationalcohortfebruary2022